Skip to main navigation
Skip to search
Skip to main content
Scholars @ UT Health San Antonio Home
Help & FAQ
Link opens in a new tab
English
Español
Search content at Scholars @ UT Health San Antonio
Home
Profiles
Research units
Publications
Datasets
Tandem autotransplantation for the treatment of metastatic breast cancer
E. Randolph Broun
, Raji Sridhara
, George W. Sledge
, David Loesch
, Patricia H. Kneebone
, Mark Hanna
,
Robert Hromas
, Kenneth Cornetta
, Lawrence H. Einhorn
Research output
:
Contribution to journal
›
Article
›
peer-review
46
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Tandem autotransplantation for the treatment of metastatic breast cancer'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Patient
100%
High Dose Chemotherapy
53%
Transplantation
20%
Cyclophosphamide
16%
Spontaneous Remission
13%
Doxorubicin
13%
Inpatient
13%
Fluorouracil
10%
Metastatic Breast Cancer
10%
Toxicity
6%
Progression Free Survival
6%
Methotrexate
6%
Bone
6%
Diseases
3%
Follow up
3%
Overall Survival
3%
Autotransplantation
3%
Combination Therapy
3%
Survival Rate
3%
Infection
3%
Tamoxifen
3%
Diarrhea
3%
Nausea and Vomiting
3%
Mucositis
3%
Prednisone
3%
Carboplatin
3%
Etoposide
3%
Peripheral Neuropathy
3%
Mitoxantrone
3%
Age
3%
Soft Tissue
3%
Therapeutic Procedure
3%
Nursing and Health Professions
Transplantation
20%
Cyclophosphamide
16%
Remission
13%
Doxil
13%
Fluorouracil
10%
Metastatic Breast Cancer
10%
Toxicity
6%
Progression Free Survival
6%
Death
6%
Methotrexate
6%
Survival Rate
3%
Follow up
3%
Diseases
3%
Infection
3%
Combination Therapy
3%
Overall Survival
3%
Autotransplantation
3%
Nausea and Vomiting
3%
Diarrhea
3%
Prednisone
3%
Peripheral Neuropathy
3%
Etoposide
3%
Laboratory
3%
Procedures
3%
Dose
3%
Mucosa Inflammation
3%
Tamoxifen
3%
Carboplatin
3%
Mitoxantrone
3%
Pharmacology, Toxicology and Pharmaceutical Science
Cyclophosphamide
16%
Remission
13%
Doxorubicin
13%
Fluorouracil
10%
Metastatic Breast Cancer
10%
Progression Free Survival
6%
Toxicity
6%
Methotrexate
6%
Death
6%
Diseases
3%
Overall Survival
3%
Tolerability
3%
Tamoxifen
3%
Diarrhea
3%
Survival Rate
3%
Nausea and Vomiting
3%
Mucosa Inflammation
3%
Infection
3%
Carboplatin
3%
Prednisone
3%
Etoposide
3%
Mitoxantrone
3%
Peripheral Neuropathy
3%
Biochemistry, Genetics and Molecular Biology
Drug Megadose
26%
Cyclophosphamide
16%
Doxorubicin
10%
Fluorouracil
10%
Methotrexate
6%
Progression Free Survival
6%
Overall Survival
3%
Survival Rate
3%
Prednisone
3%
Age
3%
Autotransplantation
3%
Dose
3%